Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans

British Journal of Pharmacology

Volumn 167, Issue 6, 2012, Pages 1195-1205

  Adage, Tiziana ^a   Piccinini, Anna Maria ^a   Falsone, Angelika ^a   Trinker, Martin ^a   Robinson, James ^a   Gesslbauer, Bernd ^a   Kungl, Andreas J ^a  

^a ProtAffin Biotechnologie AG   (Austria)

Author keywords

chemokine; glycosaminoglycan; growth factor

Indexed keywords

BINDING PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; FONDAPARINUX; GLYCOSAMINOGLYCAN; GLYPICAN 3 ANTIBODY; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN PA401; PROTEIN PA508; RANTES; SORAFENIB; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANGIOGENESIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; BINDING AFFINITY; CHRONIC INFLAMMATION; DISEASE MODEL; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; HUMAN; IN VIVO STUDY; KIDNEY ISCHEMIA; LIVER CELL CARCINOMA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RENAL GRAFT DYSFUNCTION; WILD TYPE;

ANIMALS; CHEMOKINES; GLYCOSAMINOGLYCANS; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84867769767     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02089.x     Document Type: Article

References (73)

1. Adage T, Rek A, Kungl AJ, (2010). A decoy CXCL8 with increased glycosaminoglycan binding has potent anti-inflammatory activity in lung inflammation models. European Respiratory Society Annual Meeting. Barcelona, September 18-22. Abstract 5151.
2. 35-55 EAE model of Multiple Sclerosis. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, 19-22 October. Poster topic 21- Immunomodulation 1. Poster 474.
3. Adage T, Rek A, Kungl AJ, (2011b). Pharmacological profile of a novel decoy CXCL8- based biologic therapeutic in murine models of lung inflammation. Am J Respir Crit Care Med 183: A4071.
4. th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
5. Ali S, Palmer AC, Banerjee B, Fritchley SJ, Kirby JA, (2000). Examination of the function of RANTES, MIP-1-alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. J Biol Chem 275: 11721-11727.
6. Ali S, O'Boyle G, Hepplewhite P, Tyler JR, Robertson H, Kirby JA, (2010). Therapy with nonglycosaminoglycan-binding mutant CCL7: a novel strategy to limit allograft inflammation. Am J Transplant 10: 47-58.
7. Bedke J, Nelson PJ, Kiss E, Muenchmeier N, Rek A, Behnes C-L, et al,. (2010). A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol Immunol 47: 1047-1057.
8. Bishop JR, Schuksz M, Esko JD, (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446: 1030-1037.
9. Brandner B, Rek A, Diedrichs-Möhring M, Wildner G, Kungl AJ, (2009). Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behaviour of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists. Protein Eng Des Sel 22: 367-373.
10. Campanella GS, Grimm J, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR, et al,. (2006). Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J Immunol 177: 6991-6998.
11. Campbell EJ, Owen CA, (2007). The sulphate groups of chondroitin sulphate- and heparan sulphate- containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G. J Biol Chem 282: 14645-14654.
12. Celie JWAM, Beelen RHJ, van den Born J, (2009). Heparan sulfate proteoglycans in extravasation: assisting leukocyte guidance. Front Biosci 14: 4932-4949.
13. Constantinescu AA, Vink JA, Spaan JA, (2003). Endothelial cell glycocalix modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol 23: 1541-1547.
14. Cowburn SC, Condliffe AM, Farhai N, Summers C, Chilvers ER, (2008). Advances in neutrophil biology. Clinical implications. Chest 134: 606-612.
15. Crown SE, Yu Y, Sweeney MD, Leary JA, Handel TM, (2006). Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding. J Biol Chem 281: 25438-25446.
16. Danielli JF, (1940). Capillary permeability and edema in the perfused frog. J Cell Physiol 98: 109-129.
17. Das ST, Rajagopalan L, Guerrero-Plata A, Sai J, Richmond A, Garofalo RP, et al,. (2010). Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. Plos ONE 5: e11754.
18. De Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH, (2007). Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol 2: 735-744.
19. Diedrichs-Moehring M, Nelson PJ, Proudfoot AE, Thurau SR, Wilder G, (2005). Role of CC chemokine receptor antagonist Met-RANTES in experimental autoimmune uveitis and oral tolerance induction. J Neuroimmunol 164: 22-30.
20. Esko JD, Selleck SB, (2002). Order out of chaos: assembly of ligand binding sites in Heparan Sulfate. Annu Rev Biochem 71: 435-471.
21. Fjeldstad K, Kolset SO, (2005). Decreasing the metastatic potential in cancers targeting the heparan sulphate proteoglycans. Curr Drug Targets 6: 665-682.
22. Frangogiannis NG, Smith CW, Entman ML, (2002). The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47.
23. Gangavarapu P, Rajagopalan L, Kolli D, Guerrero-Plata A, Garofalo RP, Rajarathnam K, (2012). The monomer-dimer equilibrium and glycosaminoglycan interaction of chemokine CXCL8 regulate tissue-specific neutrophil recruitment. J Leukoc Biol 91: 259-265.
24. Gesslbauer B, Kungl AJ, (2006). Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycome. Curr Opin Mol Ther 8: 521-528.
25. Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V, et al,. (2008). An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol 84: 1101-1108.
26. Harmer NJ, (2006). Insights into the role of heparan sulphate in fibroblast growth factor signalling. Biochem Soc Trans 34: 442-445.
27. Hoogewerf AJ, Kuschert GSV, Proudfoot AEI, Borlat F, Clark-Lewis I, Power CA, et al,. (1997). Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36: 13570-13578.
28. Hub E, Rot A, (1998). Binding of RANTES, MCP-1, MCP-3 and MIP-1 alpha to cells in human skin. Am J Pathol 152: 749-757.
29. Johnson Z, Proudfoot AE, Handel TM, (2005). Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 16: 625-636.
30. Krenn EC, Wille I, Gesslbauer B, Poteser M, van Kuppevelt TH, Kungl AJ, (2008). Glycanogenomics: a qPCR-approach to investigate biological glycan function. Biochem Biophys Res Commun 375: 297-302.
31. Krieger E, Geretti E, Brandner B, Goger B, Wells TN, Kungl AJ, (2004). A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations. Proteins 54: 768-775.
32. Lau EK, Paavola CD, Johnson Z, Gaudry J-P, Geretti E, Borlat F, et al,. (2004). Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1. J Biol Chem 279: 22294-22305.
33. Lensen JF, Rops AL, Wijnhoven TJ, Hafmans T, Feitz WF, Oosterwijk E, et al,. (2005). Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies. J Am Soc Nephrol 16: 1279-1288.
34. Liehn EA, Piccinini A-M, Koenen RR, Soehnlein O, Adage T, Fatu R, et al,. (2010). A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol 56: 1857-1852.
35. Lindahl U, (2007). Heparan sulfate-protein interactions-a concept for drug design? Thromb Haemost 98: 109-115.
36. Lindahl U, Backstrom G, Thunberg L, Leder IG, (1989). Evidence for a 3-O-sulfated d-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 77: 6551-6555.
37. Luft JH, (1966). Fine structures of capillary layer as revealed by ruthenium red. Fed Proc 25: 1773-1783.
38. Manakil JF, Surgerman PB, Li H, Seymour GJ, Bartold PM, (2001). Cell-surface proteoglycan expression by lymphocytes from peripheral blood and gingival in health and periodontal disease. J Dent Res 80: 1704-1710.
39. Marshall LJ, Ramdin LSP, Brooks T, Charlton P, Shute JK, (2003). Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/hparan sulfate/syndecan-1 complexes. J Immunol 171: 2057-2065.
40. Massena S, Christoffersson G, Hjertström E, Zcharia E, Vlodavsky I, Ausmees N, et al,. (2010). A chemotactic gradient sequestered on endothelial heparan sulfate induces directional crawling of neutrophils. Blood 116: 1924-1931.
41. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, et al,. (1997). Trancytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91: 385-395.
42. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA, (2002). Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100: 3853-3860.
43. Mohammadi M, Olsen SK, Goetz R, (2005). A protein canyon in the FGF-FGF receptor dimer selects from an a' la carte menu of heparan sulfate motifs. Curr Opin Struct Biol 15: 1-11.
44. Mukaida N, (2003). Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 284: L566-L577.
45. Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, et al,. (2010). Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 21: 907-916.
46. O'Boyle G, Mellor P, Kirby JA, Ali S, (2009). Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J 23: 3906-3916.
47. Paavola C, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, et al,. (1998). Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem 273: 33157-33165.
48. Petitou M, Lormeau JC, Choay J, (1988). Interaction of heparin and antithrombin III. The role of O-sulfate groups. Eur J Biochem 176: 637-640.
49. Petitou M, Lormeau JC, Choay J, (1991). A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Hemost 7 (Suppl. 2): 143-146.
50. Piccinini A-M, Knebl K, Rek A, Wildner G, Diedrichs-Möhring M, Kungl AJ, (2010). Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J Biol Chem 285: 8782-8792.
51. Potzinger H, Geretti E, Brandner B, Wabitsch V, Piccinini AM, Rek A, et al,. (2006). Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs. Biochem Soc Trans 34: 435-437.
52. Proudfoot AE, (2006). The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 34: 422-426.
53. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, et al,. (1996). Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271: 2599-2603.
54. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, et al,. (2003). Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100: 1885-1890.
55. Prydz K, Dalen KT, (2000). Synthesis and sorting of proteoglycans. J Cell Sci 113: 193-205.
56. Rahmoune H, Chen HL, Gallagher JT, Rudland PS, Fernig DG, (1998). Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem 273: 7303-7310.
57. Rek A, Brandner B, Geretti E, Kungl AJ, (2009a). A biophysical insight into the RANTES-glycosaminoglycan interaction. Biochim Biophys Acta 1794: 577-582.
58. Rek A, Krenn E, Kungl AJ, (2009b). Therapeutically targeting protein-glycan interactions. Br J Pharmacol 157: 686-694.
59. Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT, (2005). Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J Biol Chem 280: 42274-42282.
60. Rot A, (1992). Binding of neutrophil attractant/activation protein-1 (interleukin 8) to resident dermal cells. Cytokine 4: 347-352.
61. Rot A, (2010). Chemokine patterning by glycosaminoglycans and interceptors. Front Biosci 15: 645-660.
62. Sadir RA, Imberty A, Baleux F, (2004). Heparan sulphate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced cy CD26/dipeptidyl peptidase IV. J Biol Chem 279: 43854-43860.
63. Salanga CL, Handel TM, (2011). Chemokine oligomerization and interaction with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp Cell Res 317: 590-601.
64. Sarrazin S, Lamanna WC, Esko JD, (2011). Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3: 1-33.
65. Schumann K, Lämmermann T, Bruckner M, Legler DF, Polleux J, Spatz JP, et al,. (2010). Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity 32: 703-713.
66. Taylor KR, Gallo RL, (2006). Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 20: 9-22.
67. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, et al,. (1998). Beta-chemokines are releases from HIV-1-specific citolytic T-cell granules complexed to proteoglycans. Nature 391: 908-911.
68. Wang L, Fuster M, Sriramarao P, Esko JD, (2005). Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6: 902-910.
69. Weber C, Koenen RR, (2006). Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 26: 265-273.
70. Weber C, Zerneke A, Libby P, (2008). The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 810-815.
71. Weinbaum S, Tarbell JM, Damiano ER, (2007). The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9: 121-167.
72. Yang XD, Corvalan JRF, Wang P, Roy CMN, Davis CG, (1999). Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J Leukoc Biol 66: 401-410.
73. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM, (1991). Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848.